IL-4 / IL-5 / IL-13

Class

Multi-cytokine pathway inhibitor

Interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13) are cytokines that orchestrate type 2 immune responses, the branch of the immune system responsible for defending against parasites but also implicated in allergic disease. IL-4 and IL-13 act on overlapping receptor systems to promote immunoglobulin E (IgE) production, mucus secretion, and tissue remodeling in the airway and skin. IL-5 acts on a separate receptor to control the production, activation, and survival of eosinophils, a white blood cell type strongly associated with tissue damage in allergic and eosinophilic diseases. Because these three cytokines drive distinct but complementary features of type 2 inflammation, diseases such as asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps often involve more than one of these pathways simultaneously. A single agent capable of neutralizing all three cytokines is designed to interrupt both the allergic-antibody/mucus axis and the eosinophil axis at once, offering broader suppression of type 2 inflammation than an agent directed at only one cytokine. This approach is relevant wherever type 2 inflammation is a central disease driver, particularly in patients whose disease reflects mixed allergic and eosinophilic biology rather than a single dominant pathway.